Cancer Archives

News and Trends 28 Sep 2016

Little Biotechs manoeuvre to outfox Big Pharma in Immuno-Oncology

Giants like BMS and GSK have been throwing all the money they can at developing immuno-oncological treatments. In twin deals, four smaller companies are forging new paths to cure cancer with the human immune response. A pair of agreements among immuno-oncology biotechs have been made in attempts to outflank big pharma competition. In Scandinavia, Orion will fund […]

September 28, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 23 Sep 2016

SELLAS wants to sell us an Immunotherapy for Mesothelioma

After Cyprus, we mosey back to the mainland to visit the country gave the world the cuckoo clock. That’s right, we’re Schweiz-bound. In Switzerland, we’ll meet an immuno-oncology biotech, SELLAS Life Sciences. City: Zug (Zurich-area), Switzerland Founded: 2012 Employees: 11 – 50 Financial Data: None available…what a secretive cohort. Mission: SELLAS Life Sciences is a development-stage biopharmaceutical company focused on […]

September 23, 2016 - 1 minutemin - By Evelyn Warner

News and Trends 23 Sep 2016

The Munich Biotech Mafia are at it again, raising €40M for an I/O Startup

A new immuno-oncology startup has taken off with a booming round of VC fundraising. Details on its programs are sparse, but the company’s leadership is a veritable who’s who in German biotech, much like the PayPal Mafia. Immuno-oncology is surely an exciting field, but high-profile leadership is a huge bonus when it comes to attracting […]

September 23, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 21 Sep 2016

A new player has entered the Game: €29M for DDR Cancer Therapy

Artios Pharma, launched in May this year, just received €29M (£25M) in Series A to develop cancer treatments. Its technology targets the DNA-Damage Response (DDR) and could overcome one of the main challenges of cancer therapy. Top-notch investors from Europe and the US have eagerly thrown cash at Artios Pharma in their search for new cancer treatments. […]

September 21, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Sep 2016

German Biotech allies with Genentech in battle for Cancer Vaccine

BioNTech has turned up the heat in the race to bring an mRNA immunotherapy for cancer to the clinic. The German biotech has partnered with American giant Genentech in a massive deal with almost €300M upfront. Europe’s largest private biotech, BioNTech, has partnered up with Genentech to produce individualized mRNA-based cancer therapies. The collaboration aims […]

September 21, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 19 Sep 2016

Abingworth launches UK Immuno-Oncology Startup with Seed Funding

Just when we thought it couldn’t become any more intense, the field of immuno-oncology is heating up. VC giant Abingworth has seeded a new UK startup, GammaDelta Therapeutics, to bring its T cell therapy to the clinic. Abingworth, a huge British VC firm, has thrown its weight behind a new London-based immuno-oncology startup, GammaDelta Therapeutics. […]

September 19, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 12 Sep 2016

Celyad’s unique CAR-T approach is ready for Efficacy Studies

The Belgian company has completed a successful Phase I trial for its NKR-2 T-cell therapy in patients with Leukemia and Myeloma, with no safety issues or dose-limiting toxicity reported. Celyad can now embark on efficacy studies. Celyad definitely has an original story. The company started back in 2007 as Cardio3Bioscience, targeting cardiovascular diseases with cell therapy, but […]

September 12, 2016 - 2 minutesmins - By Philip Hemme

News and Trends 6 Sep 2016

“This 30M Series A will help us bring RNA Therapeutics to Immuno-Oncology”

Rigontec is taking a totally new RNA-based approach to immuno-oncology via the RIG-I receptors. The company extended its Series A fundraising to a third round, and some of the top European VC’s doubled its cash pile to almost €30M. Since launching in early 2014, Munich-based Rigontec has broken with traditional immuno-oncology and pioneered a new RNA avenue […]

September 6, 2016 - 4 minutesmins - By Evelyn Warner

News and Trends 5 Sep 2016

Amgen ties up loose ends after Largest Biotech Acquisition in Germany

Before Amgen, the largest biotech company in the world, acquired Micromet in one of the splashiest biotech deals in Europe, Micromet licensed its BiTE technology to Boehringer Ingelheim. Amgen is now taking over the development of BI’s Multiple Myeloma therapy to consolidate its hold on the bispecific antibodies. Boehringer Ingelheim has handed Amgen the keys to its Bispecific T cell […]

September 5, 2016 - 2 minutesmins - By Evelyn Warner

sylvain carlioz stimunity immunooncology2

News and Trends 5 Sep 2016

This Parisian Biotech Startup wants to clear a Major Hurdle in Immuno-oncology

Immuno-oncology is definitely the most promising breakthrough in cancer research right now. But the main issue is  that only 20-30% of patients respond to this therapy because of a weak immune system. I met Sylvain Carlioz, the co-founder of Stimunity, who wants to solve that problem. Carlioz was working at the tech transfer office of […]

September 5, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 2 Sep 2016

Roche rockets into Checkpoint Inhibitor space with Phase III Lung Cancer Success

Tecentriq could be Roche’s ticket to the top of immuno-oncology. The checkpoint inhibitor just reached its co-primary endpoints in Phase III trials for non-small cell lung cancer and could bring the company €4.5B. Roche’s Tecentriq (atezolizumab) has demonstrated that it is a force to be reckoned with by clearing Phase III clinical trials for non-small cell […]

September 2, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 1 Sep 2016

Infographic: How Cancer Starts & How It Chooses Organs

Here’s a neat infographic from Cancer Research UK summarizing a new Cell report from UK researchers that describes how conditions build to trigger cancer. This information would help to explain the greater vulnerability of certain organs to tumors compared to others. The team, headed by Richard James Gilbertson, demonstrated that while cells may start with equal carcinogenic risk, tumor […]

September 1, 2016 - 1 minutemin - By Evelyn Warner

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us